Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 1, 2025
Daily News
December 1, 2025
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- Japan’s Prescription Drug Market to Near 12 Trillion Yen in FY2030: IQVIA
December 1, 2025
- Japan Dementia Drug Market to Hit 280 Billion Yen by 2040: Fuji Keizai
December 1, 2025
- Japan Allocates 100 Billion-Plus Yen for Drug Innovation, Generic Funds: FY2025 Extra Budget
December 1, 2025
- Japan Books 15.8 Billion Yen to Boost Regenerative Medicine Manufacturing
December 1, 2025
- JFCR, NEC, Taiho Launch AI-Driven R&D for Cancer Vaccines
December 1, 2025
- Eisai Files Subcutaneous Leqembi Autoinjector in Japan
December 1, 2025
- MSD to End Gardasil Sales in Japan as Use Shifts to 9-Valent HPV Shot
December 1, 2025
- Japan Panel Labels Pregabalin for Most Low Back Pain as “Low-Value” Care
December 1, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…